SMEs contacted US FDA's drug ombudsman more often than big pharma in 2011
This article was originally published in SRA
Executive Summary
The ombudsman for the US Food and Drug Administration's drugs centre witnessed a 55% increase in contacts from commercial sponsors in 2011 compared to the previous year1. Most of these commercial sponsors were small and medium-sized entities, who contacted the ombudsman when their drug development plans hit a snag.